FDA Law Blog

JANUARY 6, 2022

In general, EKRA prohibits, knowingly and willfully, soliciting, receiving, paying or offering kickbacks in exchange for referring to, inducing a referral to, or using the services of a recovery home, clinical treatment facility, or laboratory. S&G Labs Haw., 18 U.S.C. § 18 U.S.C. § 18 U.S.C. § 18 U.S.C. § 220(b)(2).

Lab Testing 52

Lab Testing Individual Referral Patient-Centered 52

FDA Law Blog

JANUARY 6, 2022

In general, EKRA prohibits, knowingly and willfully, soliciting, receiving, paying or offering kickbacks in exchange for referring to, inducing a referral to, or using the services of a recovery home, clinical treatment facility, or laboratory. S&G Labs Haw., 18 U.S.C. § 18 U.S.C. § 18 U.S.C. § 18 U.S.C. § 220(b)(2).

Lab Testing 40

Lab Testing Individual Referral Patient-Centered 40

GeriPal

FEBRUARY 6, 2025

Eric 00:27 So we’re going to be talking about making the diagnosis of Alzheimer’s disease in a primary care setting, not specialty care, but maybe we could talk a little bit about that. So we now have blood tests that can reasonably approximate the degree of amyloid buildup in the brain. Nate 00:25 Thanks for having me.

Primary Care 96

Primary Care Diagnosis Screening IT 96